BioCentury | Oct 11, 2017
Company News

Management tracks: Aerpio, Scancell, TCR2

...development, and named Adam Thomas chief human resources officer. Gengos was president and CEO of ImmunoCellular Therapeutics Ltd....
BioCentury | Jul 14, 2017
Clinical News

ImmunoCellular suspends Phase III GBM trial of ICT-107 for lack of cash

...is unable at this time to secure sufficient additional financial resources to complete the trial. ImmunoCellular...
...unmethylated O6-methylguanine-DNA methyltransferase (MGMT) tumors and with methylated MGMT tumors, progression-free survival (PFS) and safety. ImmunoCellular...
...the trial. ICT-107 is an intradermal dendritic cell-based therapeutic vaccine that targets 6 tumor-associated antigens. ImmunoCellular Therapeutics Ltd....
BioCentury | May 11, 2017
Tools & Techniques

Stemming the tide

...NYSE:GSK) Demcizumab failed two Ph II trials, analysis ongoing; tarextumab discontinued after failing Ph II ImmunoCellular Therapeutics Ltd....
...reflects on cancer stem cells more broadly,” he told BioCentury. And while Verastem Inc. and ImmunoCellular Therapeutics Ltd....
...AG (Xetra:BAYN), Leverkusen, Germany Celgene Corp. (NASDAQ:CELG), Summit, N.J. Genentech Inc., South San Francisco, Calif. ImmunoCellular Therapeutics Ltd....
BioCentury | Feb 8, 2017
Distillery Therapeutics

Cancer

...testing tumor-associated DC-based vaccines to prevent metastasis and tumor relapse in mouse models of cancer. ImmunoCellular Therapeutics Ltd....
BioCentury | Oct 3, 2016
Finance

Reasonable rally

...NASDAQ:ACAD) 8/9/16 $230.0 $3,992.2 $3,848.2 -4% BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) 8/9/16 $720.0 $16,412.7 $15,817.8 -4% ImmunoCellular Therapeutics Ltd....
BioCentury | Aug 15, 2016
Financial News

ImmunoCellular completes follow-on

...Price: $0.16 Shares after offering: 127.8 million Underwriters: Maxim Group; Laidlaw Overallotment: 7.1 million Note: ImmunoCellular...
BioCentury | Aug 8, 2016
Clinical News

ICT-121: Completed Phase I enrollment

...weeks followed by maintenance treatment every 2 months until vaccine supply depletion or progressive disease. ImmunoCellular Therapeutics Ltd....
BioCentury | Aug 8, 2016
Financial News

ImmunoCellular amends follow-on

...million Shares: 51.5 million Price prior: $0.27 Underwriters: Maxim Group; Laidlaw Overallotment: 7.7 million Note: ImmunoCellular...
BioCentury | Jul 18, 2016
Financial News

ImmunoCellular amends follow-on

...million Shares: 60 million Price Prior: $0.27 Underwriters: Maxim Group; Laidlaw Overallotment: 9 million Note: ImmunoCellular...
BioCentury | Jun 13, 2016
Clinical News

ICT-107: Phase III started

...and every 6 months thereafter. The company has an SPA from FDA for the trial. ImmunoCellular Therapeutics Ltd....
Items per page:
1 - 10 of 95
BioCentury | Oct 11, 2017
Company News

Management tracks: Aerpio, Scancell, TCR2

...development, and named Adam Thomas chief human resources officer. Gengos was president and CEO of ImmunoCellular Therapeutics Ltd....
BioCentury | Jul 14, 2017
Clinical News

ImmunoCellular suspends Phase III GBM trial of ICT-107 for lack of cash

...is unable at this time to secure sufficient additional financial resources to complete the trial. ImmunoCellular...
...unmethylated O6-methylguanine-DNA methyltransferase (MGMT) tumors and with methylated MGMT tumors, progression-free survival (PFS) and safety. ImmunoCellular...
...the trial. ICT-107 is an intradermal dendritic cell-based therapeutic vaccine that targets 6 tumor-associated antigens. ImmunoCellular Therapeutics Ltd....
BioCentury | May 11, 2017
Tools & Techniques

Stemming the tide

...NYSE:GSK) Demcizumab failed two Ph II trials, analysis ongoing; tarextumab discontinued after failing Ph II ImmunoCellular Therapeutics Ltd....
...reflects on cancer stem cells more broadly,” he told BioCentury. And while Verastem Inc. and ImmunoCellular Therapeutics Ltd....
...AG (Xetra:BAYN), Leverkusen, Germany Celgene Corp. (NASDAQ:CELG), Summit, N.J. Genentech Inc., South San Francisco, Calif. ImmunoCellular Therapeutics Ltd....
BioCentury | Feb 8, 2017
Distillery Therapeutics

Cancer

...testing tumor-associated DC-based vaccines to prevent metastasis and tumor relapse in mouse models of cancer. ImmunoCellular Therapeutics Ltd....
BioCentury | Oct 3, 2016
Finance

Reasonable rally

...NASDAQ:ACAD) 8/9/16 $230.0 $3,992.2 $3,848.2 -4% BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) 8/9/16 $720.0 $16,412.7 $15,817.8 -4% ImmunoCellular Therapeutics Ltd....
BioCentury | Aug 15, 2016
Financial News

ImmunoCellular completes follow-on

...Price: $0.16 Shares after offering: 127.8 million Underwriters: Maxim Group; Laidlaw Overallotment: 7.1 million Note: ImmunoCellular...
BioCentury | Aug 8, 2016
Clinical News

ICT-121: Completed Phase I enrollment

...weeks followed by maintenance treatment every 2 months until vaccine supply depletion or progressive disease. ImmunoCellular Therapeutics Ltd....
BioCentury | Aug 8, 2016
Financial News

ImmunoCellular amends follow-on

...million Shares: 51.5 million Price prior: $0.27 Underwriters: Maxim Group; Laidlaw Overallotment: 7.7 million Note: ImmunoCellular...
BioCentury | Jul 18, 2016
Financial News

ImmunoCellular amends follow-on

...million Shares: 60 million Price Prior: $0.27 Underwriters: Maxim Group; Laidlaw Overallotment: 9 million Note: ImmunoCellular...
BioCentury | Jun 13, 2016
Clinical News

ICT-107: Phase III started

...and every 6 months thereafter. The company has an SPA from FDA for the trial. ImmunoCellular Therapeutics Ltd....
Items per page:
1 - 10 of 95